JP2024527963A5 - - Google Patents
Info
- Publication number
- JP2024527963A5 JP2024527963A5 JP2024504944A JP2024504944A JP2024527963A5 JP 2024527963 A5 JP2024527963 A5 JP 2024527963A5 JP 2024504944 A JP2024504944 A JP 2024504944A JP 2024504944 A JP2024504944 A JP 2024504944A JP 2024527963 A5 JP2024527963 A5 JP 2024527963A5
- Authority
- JP
- Japan
- Prior art keywords
- immune
- cells
- molecule
- subject
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021902320A AU2021902320A0 (en) | 2021-07-28 | Universal receptor immune cell therapy | |
| AU2021902320 | 2021-07-28 | ||
| PCT/AU2022/050795 WO2023004461A1 (en) | 2021-07-28 | 2022-07-28 | Universal receptor immune cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527963A JP2024527963A (ja) | 2024-07-26 |
| JP2024527963A5 true JP2024527963A5 (https=) | 2025-08-05 |
Family
ID=85085960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504944A Pending JP2024527963A (ja) | 2021-07-28 | 2022-07-28 | ユニバーサル受容体免疫細胞療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240366665A1 (https=) |
| EP (1) | EP4376855A4 (https=) |
| JP (1) | JP2024527963A (https=) |
| KR (1) | KR20240043774A (https=) |
| CN (1) | CN117915932A (https=) |
| AU (1) | AU2022316596A1 (https=) |
| CA (1) | CA3227128A1 (https=) |
| IL (1) | IL310386A (https=) |
| WO (1) | WO2023004461A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9233125B2 (en) * | 2010-12-14 | 2016-01-12 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer |
| US11377481B2 (en) * | 2015-12-22 | 2022-07-05 | The Trustees Of The University Of Pennsylvania | SpyCatcher and SpyTag: universal immune receptors for T cells |
| EP3529268B1 (en) * | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| CA3055200A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Compositions and methods for immunotherapy |
| EP4588483A3 (en) * | 2018-10-03 | 2025-09-24 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting |
| US20210107969A1 (en) * | 2019-07-09 | 2021-04-15 | The Johns Hopkins University | Molecules, compositions and methods for treatment of cancer |
| CN115397439A (zh) * | 2020-01-24 | 2022-11-25 | 宾夕法尼亚大学理事会 | 表达通用免疫受体的工程化细胞活性的定量控制 |
-
2022
- 2022-07-28 IL IL310386A patent/IL310386A/en unknown
- 2022-07-28 AU AU2022316596A patent/AU2022316596A1/en active Pending
- 2022-07-28 EP EP22847718.8A patent/EP4376855A4/en active Pending
- 2022-07-28 WO PCT/AU2022/050795 patent/WO2023004461A1/en not_active Ceased
- 2022-07-28 US US18/292,290 patent/US20240366665A1/en active Pending
- 2022-07-28 JP JP2024504944A patent/JP2024527963A/ja active Pending
- 2022-07-28 CA CA3227128A patent/CA3227128A1/en active Pending
- 2022-07-28 KR KR1020247006654A patent/KR20240043774A/ko active Pending
- 2022-07-28 CN CN202280058322.4A patent/CN117915932A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7660382B2 (ja) | 多様な多重抗原のターゲティングのための汎用的キメラ抗原受容体を発現する免疫細胞および該免疫細胞の製造方法ならびに該免疫細胞の、癌、感染症および自己免疫疾患の治療のための使用 | |
| Luo et al. | Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion | |
| JP7227290B2 (ja) | キメラ抗原受容体、組成物及び方法 | |
| CN113286879B (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| Feldman et al. | Adoptive cell therapy—tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors | |
| Mittendorf et al. | Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer: EA MITTENDORF ET AL. | |
| WO2019080872A1 (zh) | 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途 | |
| TW201900672A (zh) | 改良之抗原結合受體型式 | |
| CN114616337A (zh) | 嵌合CD3融合蛋白与基于anti-CD3的双特异性T细胞激活元件的联合表达 | |
| US20230134345A1 (en) | Chimeric antigen receptor comprising third signal receptor and use thereof | |
| Kim et al. | Chimeric antigen receptor t cells with modified interleukin-13 preferentially recognize IL13Rα2 and suppress malignant glioma: a preclinical study | |
| Han et al. | Chimeric antigen receptor modified T-cells for cancer treatment | |
| JP2018526453A (ja) | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 | |
| Ziffels et al. | Antibody-based delivery of cytokine payloads to carbonic anhydrase IX leads to cancer cures in immunocompetent tumor-bearing mice | |
| WO2025237062A1 (zh) | 一种靶向cd19和cd22的嵌合抗原受体及其car-t细胞和应用 | |
| CN114853880A (zh) | Wt1抗原特异性t细胞受体及其抗肿瘤用途 | |
| Ren‐Heidenreich et al. | Redirected T‐cell cytotoxicity to epithelial cell adhesion molecule‐overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model | |
| JP2024527963A5 (https=) | ||
| US12595307B2 (en) | Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors | |
| WO2023213280A1 (zh) | 靶向cldn18.2的嵌合抗原t细胞受体及其应用 | |
| JP2024534935A5 (https=) | ||
| Sahan Khankishiyev et al. | Current Challenges and Potential Strategies for Designing a New Generation of Chimeric Antigen Receptor-T cells with High Anti-tumor Activity in Solid Tumors | |
| US20230277666A1 (en) | Chimeric antigen receptor comprising co-stimulatory receptor and application thereof | |
| JP2021520813A5 (https=) | ||
| Khan et al. | therapy: antigen selection |